HALO
Halozyme Therapeutics, Inc. · Healthcare
Director Matthew L. Posard sold $1.7M of Halozyme Therapeutics, Inc.
Sold$1,706,550
$56.89Price
30,000Shares
−22%Stake
What HALO did after the filing
- The stock from Wed, Dec 7 open, $56.12
- −8.4%
- S&P 500, same days
- +2.4%
Measured over 30 trading days, to the Jan 23 close.
Traded Fri, Dec 2. Filed Tue, Dec 6, 7:07 PM ET, after the close. Returns use the Dec 7 open and the Jan 23 close. Not investment advice.